^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA synthesis inhibitor

    Related drugs:
    1d
    TRIM25 promotes glioblastoma progression by stabilizing HIF-1α expression in normoxia through K11/K29 polyubiquitination. (PubMed, Cell Death Dis)
    Importantly, small-molecule screening identified T7117 as an inhibitor that disrupts the TRIM25-HIF-1α interaction, suppresses tumor growth, and enhances temozolomide efficacy. Together, our findings uncover a previously unrecognized ubiquitin mechanism that stabilizes hydroxylated HIF-1α under normoxia, revealing the TRIM25-HIF-1α axis as a driver of GBM pseudohypoxia and a potential therapeutic target.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    temozolomide
    1d
    Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. (PubMed, J Immunother Cancer)
    Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B)
    |
    cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    1d
    p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells. (PubMed, Biochem Biophys Res Commun)
    p53-R248W confers selective doxorubicin resistance to multiple cancer cells through TOP2A suppression and CYP1A1/A2 overexpression. These findings highlight the mutation specific mechanism of doxorubicin resistance that might result in poor response and needs to be considered during treatment plan.
    Journal • PARP Biomarker
    |
    TOP2A (DNA topoisomerase 2-alpha) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
    |
    TP53 mutation
    |
    cisplatin • doxorubicin hydrochloride
    1d
    Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Completed, HonorHealth Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    1d
    A prospective, single-arm, exploratory clinical study evaluating the efficacy and safety of sequential intravesical instillation of LDH/EDTA combined with mitomycin C in patients with non-muscle-invasive bladder cancer. (ChiCTR2600121110)
    P=N/A, N=15, Recruiting, Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital
    New trial
    |
    mitomycin
    1d
    A Prospective Interventional Study of Temozolomide in Refractory Parathyroid Carcinoma (ChiCTR2600120647)
    P=N/A, N=25, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    New trial
    |
    temozolomide
    1d
    Study on the reduction of cardiac toxicity in children with aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation pretreatment regimen containing Thiotepa Injection (ChiCTR2600120496)
    P=N/A, N=79, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New trial
    |
    thiotepa
    2d
    A Phase I Clinical Study to Evaluate the Safety and Efficacy of Intravenous IDOV-SAFETM in Patients with Advanced Solid Tumors (ChiCTR2600118908)
    P=N/A, N=104, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New trial
    |
    IL4 (Interleukin 4) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine
    2d
    A Randomized Controlled Clinical Study of Temozolomide Concurrent Chemoradiotherapy Combined with or without Etoposide in the Treatment of Newly Diagnosed MGMT-unmethylated Glioblastoma Patients (ChiCTR2600118987)
    P=N/A, N=158, Recruiting, Cancer Research Institute of the Chinese People’s Liberation Army, Xinqiao Hospital, Army Medical University; Cancer Research Institute of the Chine
    New trial
    |
    temozolomide • etoposide IV
    2d
    A Exploratory Study on the Effect of Laser Pretreatment Combined with Local Bleomycin Therapy in the Treatment of Oral Leukoplakia (ChiCTR2600118938)
    P=N/A, N=10, Peking University School and Hospital of Stomatology; Peking University School and Hospital of Stomatology
    New trial
    |
    bleomycin
    2d
    Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    2d
    Clinical Study on Cervical Cancer: Spatial Segmentation Brachytherapy-Induced Immunotherapy Combined with Radical Concurrent Chemoradiotherapy (ChiCTR2600118216)
    P=N/A, N=15, Linfen Central Hospital; Linfen Central Hospital
    New trial • IO biomarker
    |
    cisplatin • carboplatin • Aqupla (nedaplatin)